Nektar Therapeutics Announces NKTR-255 Following CD19-Directed CAR-T Therapy Enhanced Complete Response Rates In Patients With Relapsed Or Refractory Large B-Cell Lymphoma At The 66Th Annual ASH Meeting
Nektar Therapeutics Announces NKTR-255 Following CD19-Directed CAR-T Therapy Enhanced Complete Response Rates In Patients With Relapsed Or Refractory Large B-Cell Lymphoma At The 66Th Annual ASH Meeting . (MENAFN - PR Newswire) 
  
  
 
 
 
 
 
 73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months
NKTR-255 enhanced CAR T-cell kinetics with ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108967041/Nektar-Therapeutics-Announces-NKTR-255-Following-CD19-Directed-CAR-T-Therapy-Enhanced-Complete-Response-Rates-In-Patients-With-Relapsed-Or-Refractory-Large-B-Cell-Lymphoma-At-The-66Th-Annual-ASH-Meeting
2024-12-07
rss
(MENAFN - PR Newswire) 
  
  
 
 
 
 
 
 73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months
NKTR-255 enhanced CAR T-cell kinetics with ...
Nektar Therapeutics Announces NKTR-255 Following CD19-Directed CAR-T Therapy Enhanced Complete Response Rates In Patients With Relapsed Or Refractory Large B-Cell Lymphoma At The 66Th Annual ASH Meeting